Allergia e mastocitosi in età pediatrica
Elio Novembre Dipartimento di Scienze della Salute AOU Meyer, Firenze
SIAIC Toscana-Emilia Romagna San Marino Allergia e mastocitosi in - - PowerPoint PPT Presentation
SIAIC Toscana-Emilia Romagna San Marino Allergia e mastocitosi in et pediatrica Elio Novembre Dipartimento di Scienze della Salute AOU Meyer, Firenze Cosa fare in questo bambino? Ha 8 mesi, viene per una sospetta AA : a 6 mesi vomito e
Elio Novembre Dipartimento di Scienze della Salute AOU Meyer, Firenze
Ha 8 mesi, viene per una sospetta AA : a 6 mesi vomito e
carota, finocchio semolino e 1 cucchiaio di parmigiano. Portato al DEA e trattato con antiH1. Ha anche maculo papule sul tronco e gli arti, da sempre dicono i genitori, non prudono, ma talvolta si arrossano, senza particolari fattori scatenanti. Lo visitiamo = ndn, in particolare non organomegalia, solo alcune macule rossastre su tronco e arti
Clinical classification of cutaneous mastocytosis in children* I Urticaria pigmentosa (70–90%) II Mastocytoma (10–30%) III Diffuse cutaneous mastocytosis (1–3%)
Orticaria pigmentosa
Di solito lesioni multiple; sintomi lievi
entro la pubertà
di casi
shock ipovolemico, sanguinamento.
iperpigmentazione e cute coriacea. La insorgenza neonatale può essere correlata a esito fatale.
Fried AJ Curr Asthma Report 2013 §
§ A skin biopsy is recommended unless the exam is unambiguous
Heide R et al Clin Exp Dermatol 2008 A Estensione= 1% (Mastocitoma solitario) 100%( Mastocitosi diffusa) B Intensità= 1 lesione tipica valutata in base a pigmentazione/ eritema, vescicolazione segno di Darier (0-3) C Segni soggettivi = 0-10 VALORI FRA 5.2 E 100
8 1 1 3
17.7
Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis
Clinical and Experimental Dermatology Volume 34, Issue 4, pages 462–468, June 2009
METHODS: The SCORMA Index in 64 patients (31 children and 33 adults) was compared with serum tryptase levels. The results
RESULTS: There was a positive correlation between the SCORMA Index and serum tryptase levels, indicating the value of the SCORMA Index in the assessment of mastocytosis with skin involvement. CONCLUSION: The results of this study showed that the SCORMA Index is a useful tool for evaluating the severity of cutaneous
SCORMA Index as a clinical tool. Repeated SCORMA Index measurements can provide a rapid impression of changes in the clinical state of mastocytosis. This is particularly relevant in children, because taking blood samples from this group is much more difficult.
Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis
Heide et al Clinical and Experimental Dermatology 2008
Risultato esami:
Hartmann K., et al. Int Arch Allergy Immunol 2002. Brockow K. Immunol Allergy Clin North Am 2004.
Mastocitoma (27) 20 (74%) 5 (18%) 2 (7.5%) Durata media (aa) 7.4 5.6 2.4 Orticaria pigmentosa (62) 35 (56%) 15 (24%) 12 (19.4%) Durata media (aa) 10.2 7.1 2.8
Nessuna mod.
Ben-Amitai D et al IMAJ 2005
Brockow K. Immunol Allergy Clin North Am 2014
Differences between Mast Cell Activation in Mastocytosis and during IgE-mediat ed Allergic Hypersensitivity
Mastocytosis IgE-me diated Alle rgic Hyper sensitivity Key cell Mast cell Mast cell and basophil Recep tor C-kit receptor (D816V mutation) Fc RI Mechanism Non IgE-mediated IgE-cross-linking by aller gen Triggers Nonspecific (psychological, pha rm acological, mechanica l factors and t em perature changes) Specific (IgE antib ody) Serum tryptase after t he clinical reaction Incre ased Incre ased Basal serum try ptase Usually incre ased (>20 µg/ l) in SM Less than 20 µg/ l in CM Not incre ased Skin te sts Negative Positive
Muller U et al, Allergy. 1990.
Thirty-three patients with histologically verified urticaria pigmentosa were studied for coexisting atopic disease by means of history, skin prick testing with five common inhalants and serological investigation for total IgE and specific IgE antibodies to five common inhalants. The prevalence of atopy in urticaria pigmentosa was similar to that observed in the normal Swiss population, both on the basis of history (7/33 = 21%) and of positive skin prick tests to common inhalants (12/33 = 36%). However, total serum IgE levels were significantly lower (geometric mean value 16.8 kU/l) than in a control group of 52 Swiss blood donors of comparable age and sex distribution (geometric mean value 43.0 kU/l, t = 2.93, P less than 0.005). Specific IgE antibodies to common inhalants were also observed less frequently in urticaria pigmentosa patients than in controls, although this difference was not statistically significant. Low total and specific IgE values in patients with urticaria pigmentosa may be explained by increased absorption of circulating IgE to abundant tissue mast cells.
Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA).
Gonzales de Olano D et al, Clin Exp Allergy. 2007
(WDSM), n=5; Isolated BM mastocytosis (BMM), n=3 and mastocytoma, n=1) to evaluate the history of asthma,
rhinitis, conjunctivitis,atopic dermatitis, urticaria and anaphylaxis. Patients underwent total IgE, Phadiatop infant (aeroallergens and food allergens), specific IgE to latex and to Anisakis simplex determinations. Skin tests were done to 72 patients. RESULTS: The prevalence of allergy, as defined by clinical symptoms associated to specific IgE, was 23.9%. Allergic diseases coexist in patients with mastocytosis with similar frequency as compared with the general population. The coexistence
Clinical classification of cutaneous mastocytosis in children* I Urticaria pigmentosa (70–90%) II Mastocytoma (10–30%) III Diffuse cutaneous mastocytosis (1–3%)
Storia clinica ed esami diagnostici in pazienti con orticaria pigmentosa
Prima visita (etˆ) Etˆ di comparsa Biopsia Triptasi ematica Paziente 1 2008 (4 mesi) 3 mesi No 5 Paziente 2 2014 (24 mesi) 12 mesi Si 5 Paziente 3 2013 (8,5 mesi) 1 mese Si 4 Paziente 4 2012 (26 mesi) 1 mese No 4,7 Paziente 5 2014 (12 mesi) 11 mesi No 4 Paziente 6 2014 (64mesi) 3 mesi No 5 Paziente 7 2014 (6 mesi) 6 mesi No 5
Età prima visita (media) = 20,6 mesi Età di comparsa (media) = 5,3 mesi Tript asi em atica (media) = 4,6
SOD Allergologia- Servizio Dermatologia
AA= 1/7
Storia clinica ed esami diagnostici in pazienti con mastocitoma
Prima visita (etˆ) Etˆ di comparsa Biopsia Triptasi ematica Paziente 1 2012 (24 mesi) Alla nascita No 5 Paziente 2 2011 (11 mesi) Alla nascita No 6 Paziente 3 2012 (9 mesi) 8 mesi No 5 Paziente 4 2014 (36 mesi) 24 mesi No 3 Paziente 5 2012 (15 mesi) 3,5 mesi No 6
Età prima visita (media) = 19 mesi Età di comparsa (media) = 7,1 mesi Tript asi em atica (media) = 5
SOD Allergologia- Servizio Dermatologia
AA= 0/5
Upper panel: clinical aspects of cutaneous mastocytosis (a line): left: A child with maculopapular cutaneous
mastocytosis: large red brown disseminated maculo-papules and plaques/middle: a child with diffuse cutaneous mastocytosis: diffuse skin infiltration and bullae/right: an adult with urticaria pigmentosa: little red brown disseminated macules. Middle panel: histological aspects of cutaneous mastocytosis (HES × 25) (b line): left: mast cell infiltration around blood vessels with epidermal pigmentation/middle: dense mast cell infiltration throughout the entire dermis/right: mast cell infiltration around blood vessels with vascular dilatation. Lower panel: bivariate plots displaying flow cytometric data obtained from fresh peripheral blood samples ( c line): MC precursor previously identified as CD34-CD117 + circulating cells as illustrated in adult case (circle) are absent in paediatric cases.
J Eur Acad Dermatol Venereol. 2014 Jul;28(7):967-71
I Urticaria pigmentosa (70–90%) II Mastocytoma (10–30%) III Diffuse cutaneous mastocytosis (1–3%)
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
Brockow K et al Allergy 2008 In children, the extent (A, P < 0.01) and density of skin lesions (B, P < 0.01) did correlate with anaphylaxis, but not in adults. Serum tryptase levels (C) were higher in children (P < 0.03) and adults (P < 0.01) with anaphylaxis, but diaminooxidase levels did not correlate with anaphylaxis (D)
Brockow K et al Allergy 2008
Reported complications of anesthesia in pediatric patients with mastocytosis
Source Age (years) Diagnosis Complications
. Coleman et al 4 and 5 UP None James et al. No range given 12 UP 3 mastocytoma Two rashes with codeine Damodar et al. 14 Extracutaneous mastocytoma Hypotension and bronchospasm Carter et al. 0.5–20 13 CM, 8 SM, one mastocytoma Flushing in two vomiting in four UP, urticaria pigmentosa, GA, general anesthesia
Ahmad N et al, Paediatr Anaesth. 2009 Feb;19(2):97-107.
High prevalence of anaphylaxis in patients with systemic mastocytosis – a single‐ centre experience
Gulen T et al. Clinical & Experimental Allergy 2013
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
Brockow K et al Allergy 2008
*In contrast to adult patients, hymenoptera stings played no part in eliciting anaphylaxis in children with mastocytosis.
Parents of four children reported acute anaphylactic reactions after:
Bonadonna P et al COACI 2012
Before more data on the tolerance of NSAIDs in children with mastocytosis, a cautious approach is reasonable. Children with extensive skin disease and especially active disease forming blisters, should be anaesthetized with caution (same as in adult) .
Therapy of anaphylaxis in patients with mastocytosis
Therapy Children (%) Adults (%) Epinephrine 11 Hospitalization 25 25 Antihistamines 50 61 Corticosteroids 25 46 No therapy 25 36
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
Brockow K et al Allergy 2008
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.
Brockow K1, Jofer C, Behrendt H, Ring J.
Abstract BACKGROUND: Excessive mast cell mediator release may lead to anaphylaxis in patients with mastocytosis. However, the incidence, clinical features and trigger factors have not yet been analyzed. METHODS: To identify risk factors for anaphylaxis in mastocytosis, we determined cumulative incidence, severity, clinical characteristics, and trigger factors for anaphylaxis in 120 consecutive patients (74 adults, 46 children;), and correlated these with disease severity of mastocytosis, skin involvement, basal total serum tryptase, and diaminooxidase concentrations. RESULTS: The cumulative incidence of anaphylaxis in patients with mastocytosis was higher in adults (49%; P < 0.01) compared with that in children (9%). Only children with extensive skin involvement had experienced anaphylaxis. In adults, anaphylaxis was correlated to the absence of urticaria pigmentosa lesions (P < 0.03). Reactions occurred more frequently in adults with systemic (56%) when compared with cutaneous mastocytosis (13%; P < 0.02). In adults, 48% of reactions were severe, and 38% resulted in unconsciousness. Major perceived trigger factors for adults were hymenoptera stings (19%), foods (16%), and medication (9%); however, in 26% of reactions, only a combination of different triggers preceded anaphylaxis. Trigger factors remained unidentified in 67% of reactions in children compared with 13% in adults. Patients with anaphylaxis had higher basal tryptase values (60.2 +/- 55 ng/ml, P < 0.0001) in comparison with those without (21.2 +/- 33 ng/ml), but not diaminooxidase levels. CONCLUSION: Adult patients and children with extensive skin disease with mastocytosis have an increased risk to develop severe anaphylaxis; thus, an emergency set of medication including epinephrine is recommended.
Patients with diffuse cutaneous mastocytosis: 2 years or longer follow-up and outcome
No. Onset Follow-up time Outcome Waters and Lacson 1957 1 Neonatal 5 years Died of mast cell leukaemia Orkin et al.1970 (Review) 7 1–9 months 2.5–10 years Regression of bullae, persistent cutaneous infiltration Klaber 1976 1 6 m. 25 years Leathery skin Dermographism Meneghin a 1980 1 2 months 56 years Multiple nodules, no hives, no bullae Cutaneous tumours containing mast cells Willenze et al. 1980 1 ? 25 years Multiple nodules, no hives, no bullae Cutaneous tumours containing mast cells Oku et al.1990 2 1 neonatal 5 years Hives, absence of bullae, hyperpigmentation and leathery skin No bullae, no hives Hyperpigmentation and leathery skin 1 5 months 6 years Present series 3 3–4 months 2–6 years Regression of bullae, persistent cutaneous infiltration Dermographism AE Kiszewski1, et al Journal of the European Academy of Dermatology and Venereology 2004
Lange M et al JEADV 2013; 27:97-102
Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA).
Gonzales de Olano D et al, Clin Exp Allergy. 2007 Oct;37(10):1547-55
Thirty-six adult patients (22%) with a median age of 47 years (range; 23 to 74) had a history of at least one anaphylactic episode. The percentage of males was significantly higher; 26 (72.2%)
According to the category of the disease, the prevalence of anaphylactic symptoms in adults with ISM, was similar as compared with all the remaining groups; 32/140 (22.85%) vs. 4/23 (17.39%), respectively. Among the 36 adults with anaphylactic symptoms, specific IgE against a known allergen was detected only in nine cases (25%). In the remaining 27 cases, in 15 no allergen was identified and in 12 cases clinical symptoms appeared after exposure to a known trigger such as non-steroidal anti-inflammatory drugs (n=4), -lactams (n=2) β – amoxcyllin/clavulanic, ampicillin –, hymenoptera sting (n=2), amynoglicosides (n=1) – streptomycin –, phenylephrine (n=1), general anesthesia (n=1).
Arch Med Sci. 2012 Jul 4;8(3):533-41. doi: 10.5114/aoms.2012.29409.
Mastocytosis in children and adults: clinical disease heterogeneity.
Lange M et al.